Navigation Links
Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
Date:11/13/2008

STOCKHOLM, November 13 /PRNewswire/ -- Karolinska Development AB, a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science announced today the appointment of Dr. Carl Harald Janson as investment manager.

"Carl Harald is an outstanding addition to our management team," stated Conny Bogentoft, Chief Executive Officer of Karolinska Development. "His extensive experience within the medical, pharmaceutical and investment arenas will provide an invaluable perspective for our future growth". His former activities have included work as Medical Adviser for Clinical Research and Director of Immunology for Preclinical R&D at Astra Arcus AB, Senior Financial Analyst at Hagstromer & Qviberg Fondkommission AB and Danske Securities, Danske Bank in Stockholm. He moved into fund management with companies including Carnegie Investment Bank AB.

He is a Medical Doctor holding a PhD. from Karolinska Institutet in Stockholm and qualified as a Certified European Financial Analyst at Stockholm School of Economics.

Carl Harald will take responsibility for the Karolinska Development pharma project portfolio. Bringing with him a vast network of individuals with both management and operational skills, which will further strengthen the cost effective business model used by Karolinska Development.

About Karolinska Development

Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future.

Karolinska Development's office is located at the Karolinska Institute Science Park, Sweden http://www.karolinskadevelopment.com
More about Karolinska Development: http://www.karolinskadevelopment.com

Contact: Conny Bogentoft, CEO

Tel: +46(0)8-524861-43

e-mail: info@karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. SemBioSys updates Apo AI development program
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
Breaking Biology News(10 mins):